Skip to main content
. 2020 Jul 16;12(14):14406–14417. doi: 10.18632/aging.103484

Figure 4.

Figure 4

Osthole partially reversed the cisplatin resistance of CD133+ HCC cells through the PTEN pathway. (A) QRT-PCR analysis was used to test the effect of osthole (10 μmol/L) on changing the expression of PTEN at the mRNA level. #P<0.05 vs. control group, &P<0.05 vs. cisplatin group. (B) Western blot analysis was used to evaluate the effect of osthole (10 μmol/L) and PTEN siRNA on affecting the expression of PTEN at the protein level. (C) Transfection with PTEN siRNA increased the cell viability of CD133+ Huh7 and HepG2 cells which were co-treated with osthole (10 μmol/L) and cisplatin (5 μmol/L). #P<0.05 vs. cisplatin+control siRNA group, &P<0.05 vs. cisplatin+osthole+control siRNA group. (D) Transfection with PTEN siRNA decreased the apoptotic rate of CD133+ Huh7 and HepG2 cells which were co-treated with osthole (10 μmol/L) and cisplatin (5 μmol/L). #P<0.05 vs. cisplatin+control siRNA group, &P<0.05 vs. cisplatin+osthole+control siRNA group.